• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.K. launches Innovative Medicines Review

U.K. launches Innovative Medicines Review

November 21, 2014
CenterWatch Staff

The U.K. government is launching an Innovative Medicines Review, which will consider how to speed up patient access to cost-effective and innovative medicines, devices and diagnostics.

The Innovative Medicines and MedTech Review will examine:

  • How new approaches to the development of medicines, diagnostic and devices, based on precision medicine and emerging technologies, could speed up access to innovative products for NHS patients
  • How more collaborative work between companies and regulatory and evaluation bodies could ensure that innovative products can be assessed more quickly, using better data
  • How charities and patient groups can play a greater role so that NHS patients can get access to cutting-edge treatments
  • What more can be done to promote the rapid adoption of important medical innovations into clinical practice.

In addition, a package of $98.7 million of new investment has been announced. Merck plans to invest a minimum of $65.8 million in U.K. life sciences over the next three years by creating a new licensing hub in London, expanding research at its Hertfordshire headquarters and funding clinical research in oncology and dementia. Becton, Dickinson, a global medical technology company, is investing $32.9 million to build a next generation blood separation tube production line in Plymouth. The project will create 40 jobs and safeguard 138, and is being supported by a Regional Growth Fund grant of $3.9 million.

The government is supporting investment in life sciences through the Biomedical Catalyst funding program. This funds SME and academic led projects with commercial potential.

Innovate U.K. and the Medical Research Council (MRC) now have allocated another $48.6 million of support from rounds five and six of the program. The two bodies have awarded $313.5 million to over 250 companies and universities, and gained a further $156.7 million in industry co-commitment.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing